Clinical Trials Logo

Psychotic Disorders clinical trials

View clinical trials related to Psychotic Disorders.

Filter by:

NCT ID: NCT00649064 Completed - Schizophrenia Clinical Trials

A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs

Start date: December 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see if differences exist in outcome in patients with schizophrenia or schizoaffective disorder who were switched from other antipsychotics to ziprasidone.

NCT ID: NCT00646581 Completed - Schizophrenia Clinical Trials

Effect of Single Dose Intranasal Insulin On Cognitive Function

Start date: October 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include: 1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.

NCT ID: NCT00645944 Completed - Schizophrenia Clinical Trials

Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

Start date: April 2008
Phase: N/A
Study type: Interventional

The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life. In addition, we hypothesize that the insomnia treatment may also lead to observed improvements in other symptoms associated with schizophrenia such as cognitive impairments, obesity, and negative symptoms.

NCT ID: NCT00645502 Completed - Schizophrenia Clinical Trials

Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.

Start date: June 2003
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to demonstrate the bioequivalence, with respect to risperidone and its active moiety, of a single oral dose of risperidone given as a 4 mg orally-disintegrating tablet and as a 4 mg conventional RISPERDAL tablet. In addition, their tolerability and safety will be documented.

NCT ID: NCT00644969 Completed - Smoking Cessation Clinical Trials

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

Start date: May 2008
Phase: Phase 3
Study type: Interventional

Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.

NCT ID: NCT00644852 Completed - Schizophrenia Clinical Trials

Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone

Start date: January 2007
Phase: Phase 4
Study type: Observational

The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone long-acting injectable. The goal is to evaluate patient outcomes based on pre-existing risk or disease factors and past medication use.

NCT ID: NCT00644800 Completed - Schizophrenia Clinical Trials

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

Start date: July 2003
Phase: Phase 4
Study type: Interventional

To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and others.

NCT ID: NCT00641745 Completed - Schizophrenia Clinical Trials

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Start date: March 2008
Phase: Phase 3
Study type: Interventional

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.

NCT ID: NCT00635700 Completed - Psychosis Prodrome Clinical Trials

Ziprasidone in the Psychosis Prodrome

ZIP
Start date: March 2008
Phase: Phase 2
Study type: Interventional

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

NCT ID: NCT00634348 Completed - Schizophrenia Clinical Trials

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

Start date: April 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder